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Urine represents an unlimited source of patient-specific kidney cells that can be harvested noninvasively. Urine derived podocytes
and proximal tubule cells have been used to study disease mechanisms and to screen for novel drug therapies in a variety of human
kidney disorders. The urinary kidney stem/progenitor cells and extracellular vesicles, instead, might be promising for therapeutic
treatments of kidney injury. The greatest advantages of urine as a source of viable cells are the easy collection and less complicated
ethical issues. However, extensive characterization and in vivo studies still have to be performed before the clinical use of urine-
derived kidney progenitors.
1. Introduction
Currently, dialysis and kidney transplantation are the only
successful therapies for patients suffering from chronic renal
failure. Increasing shortage of donor organs for orthotopic
kidney transplantation worldwide urges the need of alter-
native therapies. Using kidney progenitor cells might be
an alternative approach of treatment in different kidney
diseases [1]. Cells isolated from kidney tissue samples have
the advantage of coming from a defined origin. However,
they are only available in limited amounts and the life span
of mature cells in culture is short, while repeated isolations
of cells from the same donor are not allowed. On the other
hand, kidney epithelia are exposed to continuous passage of
filtrate, and thousands of living cells from healthy humans
are excreted daily [2]. These exfoliated cells from urinary
sediment can be isolated and cultured and include epithelial
cells shed from different parts of the nephrons, ureters,
bladder, and urethra [3] representing a limitless source of
noninvasively harvested viable cells.
Themain types of exfoliated kidney cells in urine demon-
strated so far are podocytes, proximal tubular cells, and
undifferentiated cells called kidney stem/progenitor cells.
Extracellular vesicles are also present in urine and can be an
interesting source for studying the disease mechanisms and
prognosis, aswell as a potential regenerative stimulus through
their paracrine effect [4] (Table 1 and Figure 1).
The use of urinary cells entails less ethical concerns and,
most importantly, reduces immune response and rejection
when applied in an autologous manner. As for all types of
cells, prior to clinical use, further studies need to be per-
formed to improve the isolation, culture, and differentiation
steps to deliver cells with consistent number, quality, and
stability.
2. Differentiated Kidney Cells
Isolated from Urine
2.1. Podocytes. Podocytes are mature epithelial cells with
a complex cellular organization consisting of a cell body,
major processes, and foot processes. Interdigitating foot
processes of neighboring podocytes form the slit diaphragm,
and together they cover the outer part of the glomerular
basement membrane playing a major role in establishing
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Table 1: Types of kidney cells exfoliated in urine and their current applications.
Urine-derived
kidney cell Markers of disease activity Disease modeling
Studying cell
biology/physiology Therapeutic effects
Podocytes
(i) Diabetic nephropathy [13, 17]
(ii) Membranous nephropathy [61]
(iii) Focal and segmental
glomerulosclerosis [11]
(iv) Henoch-Scho¨nlein nephritis
(v) IgA nephritis
(vi) Lupus nephritis [9, 15]
(vii) Preeclampsia [18]
(viii) D + HUS [62]
(ix) Diffuse mesangial sclerosis [63]
(i) Lupus nephritis [16] (i) Characterization [22](ii) Function [64, 65] Not studied
PTECs (i) Acute tubular necrosis [66, 67](ii) Diabetes mellitus [67]
(i) Cystinosis [23, 24, 27]
(ii) Diabetes mellitus [67]
(iii) Hyperoxaluria [26]
(iv) Dent disease [29]
(v) Lowe syndrome [68]
(i) Characterization [30]
(ii) Function [28, 30, 69]
(i) Paracrine effects of
conditioned medium
[70]
Stem/
progenitors Not studied Not studied
(i) Characterization
[37, 38, 42, 43, 71, 72]
(i) Differentiation into
glomerular cells [38, 73]
(ii) Genitourinary tissue
reconstruction [74–76]
(iii) Skeletal muscle
regeneration [50, 77, 78]
(iv) Neurologic tissue
reconstruction [79]
Extracellular
vesicles
(i) Focal and segmental
glomerulosclerosis [80, 81] Not studied
(i) Characterization
[53, 81–84]
(ii) Function [53]
(i) Kidney
transplantation [57]
Podocytes
PTECs Immortalization
Study disease mechanisms
Novel drug therapy identification
Cell therapy/kidney regeneration
Diagnosis, prognosis, and therapy
Stem/progenitor cells
Extracellular vesicles
}
Figure 1: Urine as source of specific kidney cells and extracellular vesicles: applications and future perspectives.
the selective permeability of the glomerular filtration barrier,
which explains why podocyte injury is typically associated
with marked proteinuria [5].
Since the 70s different techniques have been used for
the isolation of podocytes directly from the glomeruli [6, 7].
However, podocytes can also be isolated from human urine,
both fromhealthy subjects or patients with glomerulopathies,
representing a noninvasive source of viable cells [8]. The
quantification of podocytes in urine can be performed by
immunofluorescence using specific antibodies such as anti-
podocalyxin [9–11] or by isolation of the podocyte specific
mRNA products (e.g., podocin or nephrin) [12].
Usually, higher numbers of podocytes are found in urine
of patients with glomerular diseases compared to healthy
subjects and those cells show faster ex vivo proliferation rate
[11, 13]. For example, in patients with focal and segmental
glomerulosclerosis (FSGS), podocyte loss increases in accor-
dance to the level of injury and might be a marker of disease
progression [11, 14]. Besides FSGS, urinary podocytes have
been detected during the acute phase of other diseases, such
as Henoch-Scho¨nlein nephritis [10], IgA nephropathy [10],
lupus nephritis [9, 15, 16], and also diabetic nephropathy
[17] and preeclampsia [18]. Moreover, it has been suggested
that urinary excretion of podocytes might be helpful to
discriminate between acute and chronic stages of glomerular
damage [19].
The loss of podocytes in urine has been also demonstrated
in healthy individuals [14]. Interestingly, in healthy subjects
most of the shed podocytes are senescent, while in experi-
mental or human disease conditions a lot of viable podocytes
are excreted [20].
Because of the limited proliferation rate and short life
span of podocytes in culture, the immortalization step is
instrumental for theirmaintenance. In 2002, Saleem et al. [21]
developed a human conditionally immortalized podocyte cell
line expressing specifically nephrin and podocin and later, in
2010, Sakairi et al. [22] created long-term urinary cell cultures
from FSGS patients and healthy volunteers, showing that
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both cell lines present similar podocyte features [22]. These
immortalized podocytes are transformed by insertion of a
temperature-sensitive mutant of the proto-oncogene, SV40
large T antigen, so that they dedifferentiate and replicate
under permissive conditions at 33∘C, allowing unlimited
turnover of cells, and regain a podocyte phenotype under
nonpermissive conditions at 37∘C [20].
2.2. Proximal Tubule Epithelial Cells (PTECs). The proximal
tubules are the primary targets in numerous inherited and
acquired conditions such as in ischemic or toxic kidney injury
or genetic Fanconi syndromes [23].
In 1991, Racusen et al. [24] were the first to show
that viable PTECs could be isolated from human urine of
patients with nephropathic cystinosis, a lysosomal storage
disease causing renal Fanconi syndrome. Do¨rrenhaus et al.
[3], in 2000, described proximal tubules urine cell colonies
designated as type-2 colonies with a cobblestone-like mor-
phology. These cells were able to form domes caused by the
transepithelial fluid transport from the medium to the area
between the culture plate surface and the cells monolayer
[3]. Later on, three-dimensional collagen gel cultures were
established using PTECs from human urine to drive them to
a highly polarised state. And because the cells still had some
proliferative potential and became polarized, they were able
to form organised structures resembling the in vivo tubules
[25].
Interestingly, the number of urinary PTECs does not
always correspond to the degree of kidney injury, as for
example, in primary hyperoxaluria; a higher number of
exfoliated PTECs in urine were not detected [26]. Anyhow,
lots of viable proximal tubule cells are voided in human urine
and they can be exploited for physiological studies such as
analysing the transport of drugs and different substances in
the proximal tubules. Again, the limitations of using PTECs
in culture are the limited cells number and short life span
that can be overcome by the conditional immortalization of
the cells. The first immortalized proximal tubule cell line was
generated by Racusen et al. in 1995 [27].The next cell line was
only established in 2010, when Wilmer et al. [28] developed
conditionally immortalized PTECs from urine of healthy
subjects. These cells expressed multiple endogenous organic
ion transporters, mimicking renal reabsorption and excre-
tion. Shortly afterwards, another conditionally immortalized
PTECs line was established from the urine of cystinotic
patients [23].
Conditionally immortalized PTECs are useful models
to explore the mechanisms involved in specific proximal
tubular renal pathologies. Gorvin et al. [29] have used urinary
PTECs lines of patients with Dent’s disease to study receptor
mediated endocytosis and endosomal acidification depend-
ing on the type of mutation in the CLCN5 gene causing this
condition. Urinary PTECs have been also applied for in vitro
studies of cell physiology and toxicology, including the influx
and efflux of drugs [28], and might represent a promising
step towards a bioartificial kidney device [30]. In 2004, an
FDA-approved phase I/II clinical trial that was performed in
10 patients using PTECs harvested from human kidneys in a
bioartificial kidney demonstrated that the addition of human
PTECs to replacement therapy improves metabolic activity
with systemic effects in patients with acute renal failure and
multiorgan failure [31]. Later, in 2008 a phase II randomized
trial using the same device with nonautologous PTECs
showed more rapid recovery of kidney function in critically
ill patients with acute renal failure [32]. Presenting similar
genetic and functional characteristics as kidney harvested
PTECs [30], the urinary cells might have great advantage
of possible autologous cell therapy that has to be further
evaluated.
3. Undifferentiated Kidney Cells
Isolated from Urine
During nephrogenesis, stem/progenitor cells are located
in the cap mesenchyme and behave as true committed
stem cells, capable of self-renewing and differentiation into
different types of nephron epithelia [33, 34]. These cells
express specific renal progenitor cells markers as SIX2 [34],
Cited1 [33], NCAM, ep-CAM, and FZD7 [35] and have been
extensively characterized. As amniotic fluid (AF) is mainly
composed of fetal urine and lung exudates [36], it is believed
that some subpopulations of AF cells are of kidney origin
and are committed to renal fates. Indeed, amniotic fluid is
believed to be an important source of stem cells in an interme-
diate stage between embryonic stem cells and adult stem cells.
Da Sacco et al. [37] have successfully isolated a subpopulation
of metanephric mesenchyme-like cells from AF and later
showed that these cells are committed to nephron lineages,
being capable to differentiate into functional podocytes [38].
These cells represent a new model to study podocyte cell
biology and development. Additionally, the isolated renal
committed stem cells from AF can be an attractive source of
cells to repair kidney injury.
It is known that, in humans, nephrogenesis is completed
at about 34–36 weeks of gestational age. Thus, the presence
of stem/progenitor cells in the adult human kidney is highly
discussed, as well as their possible origins. Initially, CD133+
cells presenting progenitor cells characteristics were isolated
from adult renal cortex [39]. Subsequently, these cells were
found in different segments of the nephrons as the urinary
pole of the Bowman’s capsule [40], in the proximal tubules
and the inner medullary papilla region, including Henle’s
loop and the S3 limb segment [41]. In agreement with the idea
of an existent stem cell-like population in mature kidneys,
it has been demonstrated that freshly voided urine [42] and
urine from the upper urinary tract [43] contain stem cells
capable to reconstruct urological tissues. Contrasting these
results, other groups have shown that the repair of acute
injured renal tubules does not involve specialized kidney
progenitors [44] but occurs from resident differentiated
tubular cells that had survived the injury and underwent
dedifferentiation [45] in response to damaging factors that
may give them a higher proliferation capacity, the ability
to redifferentiate and reintegrate the injured site. Regarding
podocyte regeneration, it has been shown using linage fate
tracing that cells of renin lineage from juxta-glomerular
apparatus might represent progenitor cells in glomerular
disease [46, 47].
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The effectiveness of kidney stem/progenitor cell trans-
plantation in animal models of kidney injury has been
described using tissue progenitor cells from embryonic [48]
and adult kidneys [47, 49]. Human embryonic nephron
progenitor NCAM+ cells were engrafted and integrated
in diseased murine kidneys and had beneficial effects
on renal function halting disease progression in the 5/6-
nephrectomy kidney injury model [48]. The injection of
adult kidney CD133+CD24+PDX− cells in an adriamycin-
induced nephropathymousemodel showed reduced protein-
uria and improved chronic glomerular damage [47], while
CD133+CD24+CD106+ cells injected in SCID mouse with
acute tubular injury were able to generate novel tubular cells
and improve renal function [49]. Moreover, the therapeutic
effect of urine-derived stem cells was tested on athymic
mouse model and VEGF-expressing urine-derived stem cells
combined with human umbilical venous endothelial cells
were used for treating vesicoureteral reflux and stress urinary
incontinence [50]. These cells have also been effective in the
development of a multilayer mucosal structure similar to that
of native urinary tract tissue when seeded on 3D porous small
intestinal submucosa scaffold and may serve as an alternative
cell source in cell-based tissue engineering [51]. However, the
therapeutic potential of urinaryKSPCs in renal injury still has
to be studied.
Altogether, these studies confirm the importance of urine
as a noninvasive source of viable cells with potential for
regenerative medicine and tissue engineering, in addition to
cytotoxicity and pharmacological studies.
4. Urinary Extracellular Vesicles (EVs)
Extracellular vesicles (EVs) are small particles (100–1000 nm)
secreted by all types of cells under both physiological and
pathological conditions.They are composed by a lipid bilayer,
which encloses several cytoplasmic proteins, lipids as well
as nucleic acids, comprising their biological “cargo” [52–54].
Due to their apparently important role in cell-cell commu-
nication, EVs have gained an increasing interest during the
last decades whereas numerous studies demonstrate their
isolation from various body fluids, including urine [53]. As
the content of EVs may reflect both the cell of origin and
its pathophysiological state, urinary EVs represent a unique
source of information for diagnostic purposes andmay possi-
bly display therapeutic functions along with stem/progenitor
cells.
Recent studies provide evidence that uEVs present in
the preurine may transfer information within the nephron
segments, thus representing a mechanism of intranephron
communication [55, 56]. Urinary EVs derive from every
epithelial cell of the kidney, including renal progenitor cells.
In this regard, Dimuccio et al. showed absence of CD133+ uri-
nary EVs in patients suffering from end stage kidney disease,
underlying the possible exhaustion of CD133+ progenitors in
these patients [57]. Moreover, lower levels of CD133+ uEVs
were present in delayed graft compared to early graft recovery,
suggesting a possible correlation between levels of CD133+
vesicles in urine and the renal homeostasis or recovery after
injury [57].
Finally, EVs are known to recapitulate the therapeutic
effect of stem cells, due to their paracrine effects, resulting in
a horizontal transfer of mRNA, microRNA, and proteins [52,
58–60]. In particular, mesenchymal stem cell-derived EVs
stimulated proliferation and apoptosis resistance of tubular
epithelial cells in vitro [59] and accelerated themorphological
and functional recovery in vivo in different experimental
animal models of renal injury [58, 60]. Within the urinary
EVs, it is therefore possible that progenitor-derived EVs may
be involved in local paracrine effect on neighboring cells,
directing differentiation or regenerative programs.
Therefore, considering that every epithelial cell of the
kidneymay secret vesicles into the urinary space, urinary EVs
may be used as markers of prognosis, diagnosis, and therapy
of several kidney diseases.
5. Advantages, Limitations, and
Future Challenges
The use of urine as source of kidney cells has great advan-
tages compared to tissue harvesting due to the noninvasive
methods of collection; it raises less ethical concerns, once
urine is a excreted product of the body; many samples can
be collected from the same individual, allowing investigation
of disease progression and its treatments; cells could be
used for autologous therapy avoiding immune rejection
after transplantation due to antigenic differences; and very
importantly, the cells collected in urine are viable, are able
to proliferate in culture, and present similar features of cells
harvested from kidney tissue.
However, culture of kidney cells presents some limitations
because of the maturity of the cells. If urinary kidney
stem/progenitor cells were able to differentiate into fully
mature and functional kidney cells, they could overcome this
problem.
In the future though, human renal cells isolated from
urine might play a role in tissue engineering for personalized
medicine in patients suffering from nephropathies or chronic
renal disease. Bioartificial kidneys in combinationwith autol-
ogous kidney cells could help to improve kidney function
and its outcomes. However before that, a full characterization
and a rigorous selection of the cells should be done for safe
implementation in clinical applications.
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